MPS Pharmaa Ltd vs CIPLA LTD

A side-by-side comparison of MPS Pharmaa Ltd (531686) and CIPLA LTD (CIPLA) — valuation, profitability, growth, and financial health — to help you judge which is the stronger buy today.

The verdict

On the numbers, CIPLA LTD leads 531686 vs CIPLA on 10 of 14 metrics (2 undecided). See the breakdown below — the right pick still depends on your goals (value vs growth, risk appetite).

  • Valuation13
  • Profitability04
  • Growth· not comparable
  • Size & financial health13

Valuation

CIPLA takes 3/4

How expensive each stock is relative to its earnings and book value. Lower usually means cheaper.

0.00
P/E ratio
29.32
53.27
P/B ratio
3.42
0.00%
Dividend yield
0.92%
₹-0.47
EPS
₹48.02

Profitability

CIPLA takes 4/4

How efficiently each company turns capital and sales into profit. Higher is better.

-83.30%
Return on equity
11.60%
-9.79%
Return on capital
15.00%
0.00%
EBITDA margin
21.00%
0.00%
Net margin
13.71%

Growth

Three-year compounded growth. Faster-growing businesses can justify a higher valuation.

Revenue CAGR (3Y) even
7.37%
Profit CAGR (3Y) even
10.88%

Size & financial health

CIPLA takes 3/4

Scale and balance-sheet strength. Bigger revenue/profit and lower debt are generally safer.

₹7 Cr
Market cap
₹1.14L Cr
₹0 Cr
Revenue
₹28,163 Cr
₹-1 Cr
Net profit
₹3,862 Cr
0.00
Debt / equity
0.00
MPS Pharmaa Ltd
  • ["Stock is trading at 54.3 times its book value", "Company has low interest coverage ratio.", "Promoter holding is low: 35.9%", "Company has a low return on equity of -61.4% over last 3 years.", "Company might be capitalizing the interest cost"]
CIPLA LTD
  • + ["Company is almost debt free.", "Company has been maintaining a healthy dividend payout of 25.7%"]
  • ["The company has delivered a poor sales growth of 8.01% over past five years.", "Promoter holding has decreased over last 3 years: -4.24%"]
MPS Pharmaa Ltd full analysis CIPLA LTD full analysis

This comparison is for informational purposes only and is not investment advice. Please consult a SEBI-registered advisor before investing.